全肩关节置换术患者在接受长效神经阻滞与多模式镇痛后经历怎样的疼痛水平
这项前瞻性观察研究纳入102例全肩关节置换术患者,所有患者接受单次注射布比卡因肌间沟臂丛阻滞(辅以可乐定、地塞米松和丁丙诺啡)及多模式镇痛。术后第14天活动时疼痛评分中位数为3分,低于术前中位数7分;阿片类药物使用在中位第7天后停止。
要点
- 术后第14天活动时数字评分量表疼痛中位数为3分(四分位距1-5),低于术前中位数7分(四分位距5-9)。
- 术后第1、3、14天活动时疼痛中位数分别为2分、5分、3分。
- 中位总阿片类药物用量在最初24小时为16 mg口服吗啡当量,第3个24小时为30 mg,至第8个24小时降至0 mg。
核心结论
- 采用长效单次注射神经阻滞联合多模式镇痛的临床医生可告知全肩关节置换术患者,术后疼痛可能低于术前疼痛,且平均在7天后停止使用阿片类药物。
研究设计与样本
- 前瞻性、机构审查委员会批准的观察性研究,2017年1月27日至2017年12月6日共识别154例潜在合格的全肩关节置换术患者,排除46例(30%)及6例(4%)随访数据不完整者,最终102例(66%)纳入分析。
主要发现
- 术前活动时疼痛中位数为7分(四分位距5-9),102例患者中13例术前使用阿片类药物。
- 术后第1天活动时数字评分量表疼痛中位数为2分(四分位距0-5),术后第3天为5分(四分位距3-6),术后第14天为3分(四分位距1-5)。
- 中位总阿片类药物用量(转换为口服吗啡当量)在最初24小时为16 mg(4-50 mg),第3个24小时为30 mg(8-63 mg),至第8个24小时为0 mg(0-20 mg),静脉患者自控镇痛装置激活次数最常见为0次。
- 术后第1天阿片类药物相关症状困扰量表复合评分中位数为0.3(四分位距0.1-0.5);术后第1天和术后第14天PainOut问卷中睡眠干扰、恶心、嗜睡和瘙痒的中位数均为0。
临床怎么用
- 作者认为,使用该方案(长效单次注射神经阻滞联合多模式镇痛)的临床医生可告知全肩关节置换术患者术后疼痛可能低于术前,且平均在7天后停止使用阿片类药物。
局限性
- 未来研究可探讨该方案中各组成部分的贡献。
- 需要更大型的队列研究或登记研究来记录罕见并发症的发生率。
- 随机对照试验可直接比较该方案与替代策略(如神经周围导管或脂质体布比卡因)的镇痛效果和成本效益。
- 未来研究可寻求进一步降低术后第2天和第3天峰值疼痛及阿片类药物用量的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pain experience for total shoulder arthroplasty (TSA) patients in the first 2 weeks after surgery has not been well described. Many approaches to pain management have been used, with none emerging as clearly superior; it is important that any approach minimizes postoperative opioid use. QUESTIONS/PURPOSES: (1) With a long-acting nerve block and comprehensive multimodal analgesia, what are the pain levels after TSA from day of surgery until postoperative day (POD) 14? (2) How many opioids do TSA patients take from the day of surgery until POD 14? (3) What are the PainOUT responses at POD 1 and POD 14, focusing on side effects from opioids usage? METHODS: From January 27, 2017 to December 6, 2017, 154 TSA patients were identified as potentially eligible for this prospective, institutional review board-approved observational study. Of those, 46 patients (30%) were excluded (either because they were deemed not appropriate for the study, research staff were not available, patients were not eligible, or they declined to participate), and another six (4%) had incomplete followup data and could not be studied, leaving 102 patients (66%) for analysis here. Median preoperative pain with movement was 7 (interquartile range [IQR], 5-9) and 13 of 102 patients used preoperative opioids. All patients received a single-injection bupivacaine interscalene block with adjuvant clonidine, dexamethasone, and buprenorphine. Multimodal analgesia included acetaminophen, NSAIDs, and opioids. The primary outcome was the Numerical Rating Scale (NRS) pain score with movement on POD 14. The NRS pain score ranges from 0 (no pain) to 10 (worst pain possible). Secondary outcomes included NRS pain scores at rest and with movement (day of surgery, and PODs 1, 3, 7 and 14), daily analgesic use from day of surgery to POD 14 (both oral and intravenous), Opioid-Related Symptom Distress Scale (which assesses 12 symptoms ranging from 0 to 4, with 4 being the most distressing; the composite score is the mean of the 12 symptom-specific scores) on POD 1, and the PainOut questionnaire on POD 1 and POD 14. The PainOut questionnaire includes questions rating nausea, drowsiness, itching from 0 (none) to 10 (severe), as well as rating difficulty staying asleep from 0 (does not interfere) to 10 (completely interferes). RESULTS: The median NRS pain scores with movement were 2 (IQR, 0-5) on POD 1, 5 (IQR, 3-6) on POD 3, and the pain score was 3 (IQR, 1-5) on POD 14. Median total opioid use (converted to oral morphine equivalents) was 16 mg (4-50 mg) for the first 24 hours, 30 mg (8-63 mg) for the third, and 0 mg (0-20 mg) by the eighth 24-hour period, while the most frequent number of activations of the intravenous patient-controlled analgesia device was 0. Median PainOut scores on POD 1 and POD 14 for sleep interference, nausea, drowsiness and itching were 0, and the median composite Opioid-Related Symptom Distress Scale score on day 1 was 0.3 (IQR, 0.1-0.5). CONCLUSIONS: Clinicians using this protocol, which combines a long-acting, single-injection nerve block with multimodal analgesia, can inform TSA patients that their postoperative pain will likely be less than their preoperative pain, and that on average they will stop using opioids after 7 days. Future research could investigate what the individual components of this protocol contribute. Larger cohort studies or registries would document the incidence of rare complications. Randomized controlled trials could directly compare analgesic effectiveness and cost-benefits for this protocol versus alternative strategies, such as perineural catheters or liposomal bupivacaine. Perhaps most importantly, future studies could seek ways to further reduce peak pain and opioid usage on POD 2 and POD 3. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- YaDeau JT, Dines DM, Liu SS, et al. What Pain Levels Do TSA Patients Experience When Given a Long-acting Nerve Block and Multimodal Analgesia? Clin Orthop Relat Res. 2019. PMID: 30762694. doi:10.1097/CORR.0000000000000597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。